| Dr Jason M Lee-llacer, MD | |
|
2001 Medical Pkwy, Acute Care Pavilion, Annapolis, MD 21401-3280 | |
| (443) 481-1000 | |
| Not Available |
| Full Name | Dr Jason M Lee-llacer |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 21 Years |
| Location | 2001 Medical Pkwy, Annapolis, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497810378 | NPI | - | NPPES |
| 206362 | Other | JHHC | |
| 0042 | Other | CAREFIRST | |
| 89550101 | Other | CAREFIRST | |
| 145724700 | Other | DEPT. OF LABOR | |
| 263508 | Other | KAISER | |
| 1503640 | Other | AETNA HMO | |
| 318699 | Other | AMERIGROUP | |
| 412132500 | Medicaid | MD | |
| 7132906 | Other | AETNA PPO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | D0064818 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Doctors' Community Hospital | Lanham, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Luminis Health Medical Group, Llc | 2860447315 | 431 |
| Luminis Health Medical Group, Llc | 2860447315 | 431 |
News Archive
Osiris Therapeutics, Inc. announced today that the Biologics and Genetic Therapies Directorate of Health Canada has completed its initial evaluation and accepted for full review the company's New Drug Submission (NDS) of Prochymal (remestemcel-L), an adult stem cell therapy for the treatment of graft vs. host disease (GvHD). Based on a separate review of summary clinical data, Health Canada has notified Osiris that the application has been granted Priority Review, shortening the examination period from 300 to 180 days.
For many students away from home for the first time, college marks the first time they begin shopping, cooking and eating for themselves. Figuring out how to prepare quick yet healthy meals on a budget can be a daunting task, and the allure of fast take-out food often leads to the dreaded "Freshman Fifteen."
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced key findings from preclinical studies of the Company's novel cancer metabolism inhibitor (CMI), MPC-9528, at the Cancer and Metabolism Pathways to the Future Symposium in Edinburgh, Scotland.
Palonosetron 20 μg/kg is noninferior to ondansetron for the control of chemotherapy-induced vomiting and nausea during the acute phase of the first treatment cycle in paediatric patients with cancer, research shows.
More than 40 million Americans face a high risk of developing Type 2 diabetes, and it would cost a lot to give all of them intensive help with diet and exercise, or medication, to keep them from developing diabetes.
› Verified 1 days ago
| Entity Name | Emergency Medicine Associates Pa Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134117393 PECOS PAC ID: 8022914522 Enrollment ID: O20040126000955 |
News Archive
Osiris Therapeutics, Inc. announced today that the Biologics and Genetic Therapies Directorate of Health Canada has completed its initial evaluation and accepted for full review the company's New Drug Submission (NDS) of Prochymal (remestemcel-L), an adult stem cell therapy for the treatment of graft vs. host disease (GvHD). Based on a separate review of summary clinical data, Health Canada has notified Osiris that the application has been granted Priority Review, shortening the examination period from 300 to 180 days.
For many students away from home for the first time, college marks the first time they begin shopping, cooking and eating for themselves. Figuring out how to prepare quick yet healthy meals on a budget can be a daunting task, and the allure of fast take-out food often leads to the dreaded "Freshman Fifteen."
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced key findings from preclinical studies of the Company's novel cancer metabolism inhibitor (CMI), MPC-9528, at the Cancer and Metabolism Pathways to the Future Symposium in Edinburgh, Scotland.
Palonosetron 20 μg/kg is noninferior to ondansetron for the control of chemotherapy-induced vomiting and nausea during the acute phase of the first treatment cycle in paediatric patients with cancer, research shows.
More than 40 million Americans face a high risk of developing Type 2 diabetes, and it would cost a lot to give all of them intensive help with diet and exercise, or medication, to keep them from developing diabetes.
› Verified 1 days ago
| Entity Name | Luminis Health Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073580205 PECOS PAC ID: 2860447315 Enrollment ID: O20050317000146 |
News Archive
Osiris Therapeutics, Inc. announced today that the Biologics and Genetic Therapies Directorate of Health Canada has completed its initial evaluation and accepted for full review the company's New Drug Submission (NDS) of Prochymal (remestemcel-L), an adult stem cell therapy for the treatment of graft vs. host disease (GvHD). Based on a separate review of summary clinical data, Health Canada has notified Osiris that the application has been granted Priority Review, shortening the examination period from 300 to 180 days.
For many students away from home for the first time, college marks the first time they begin shopping, cooking and eating for themselves. Figuring out how to prepare quick yet healthy meals on a budget can be a daunting task, and the allure of fast take-out food often leads to the dreaded "Freshman Fifteen."
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced key findings from preclinical studies of the Company's novel cancer metabolism inhibitor (CMI), MPC-9528, at the Cancer and Metabolism Pathways to the Future Symposium in Edinburgh, Scotland.
Palonosetron 20 μg/kg is noninferior to ondansetron for the control of chemotherapy-induced vomiting and nausea during the acute phase of the first treatment cycle in paediatric patients with cancer, research shows.
More than 40 million Americans face a high risk of developing Type 2 diabetes, and it would cost a lot to give all of them intensive help with diet and exercise, or medication, to keep them from developing diabetes.
› Verified 1 days ago
| Entity Name | Anacostia Medical Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376973362 PECOS PAC ID: 8123257821 Enrollment ID: O20190219000024 |
News Archive
Osiris Therapeutics, Inc. announced today that the Biologics and Genetic Therapies Directorate of Health Canada has completed its initial evaluation and accepted for full review the company's New Drug Submission (NDS) of Prochymal (remestemcel-L), an adult stem cell therapy for the treatment of graft vs. host disease (GvHD). Based on a separate review of summary clinical data, Health Canada has notified Osiris that the application has been granted Priority Review, shortening the examination period from 300 to 180 days.
For many students away from home for the first time, college marks the first time they begin shopping, cooking and eating for themselves. Figuring out how to prepare quick yet healthy meals on a budget can be a daunting task, and the allure of fast take-out food often leads to the dreaded "Freshman Fifteen."
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced key findings from preclinical studies of the Company's novel cancer metabolism inhibitor (CMI), MPC-9528, at the Cancer and Metabolism Pathways to the Future Symposium in Edinburgh, Scotland.
Palonosetron 20 μg/kg is noninferior to ondansetron for the control of chemotherapy-induced vomiting and nausea during the acute phase of the first treatment cycle in paediatric patients with cancer, research shows.
More than 40 million Americans face a high risk of developing Type 2 diabetes, and it would cost a lot to give all of them intensive help with diet and exercise, or medication, to keep them from developing diabetes.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jason M Lee-llacer, MD Po Box 64916, Baltimore, MD 21264-4916 Ph: (443) 481-6467 | Dr Jason M Lee-llacer, MD 2001 Medical Pkwy, Acute Care Pavilion, Annapolis, MD 21401-3280 Ph: (443) 481-1000 |
News Archive
Osiris Therapeutics, Inc. announced today that the Biologics and Genetic Therapies Directorate of Health Canada has completed its initial evaluation and accepted for full review the company's New Drug Submission (NDS) of Prochymal (remestemcel-L), an adult stem cell therapy for the treatment of graft vs. host disease (GvHD). Based on a separate review of summary clinical data, Health Canada has notified Osiris that the application has been granted Priority Review, shortening the examination period from 300 to 180 days.
For many students away from home for the first time, college marks the first time they begin shopping, cooking and eating for themselves. Figuring out how to prepare quick yet healthy meals on a budget can be a daunting task, and the allure of fast take-out food often leads to the dreaded "Freshman Fifteen."
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced key findings from preclinical studies of the Company's novel cancer metabolism inhibitor (CMI), MPC-9528, at the Cancer and Metabolism Pathways to the Future Symposium in Edinburgh, Scotland.
Palonosetron 20 μg/kg is noninferior to ondansetron for the control of chemotherapy-induced vomiting and nausea during the acute phase of the first treatment cycle in paediatric patients with cancer, research shows.
More than 40 million Americans face a high risk of developing Type 2 diabetes, and it would cost a lot to give all of them intensive help with diet and exercise, or medication, to keep them from developing diabetes.
› Verified 1 days ago
Gashaw Adugna Dadi, M.D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2001 Medical Pkwy, Annapolis, MD 21401 Phone: 240-495-4189 | |
Dr. Eugene Thomas Manion, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 900 Bestgate Road, Suite 303, Annapolis, MD 21401 Phone: 410-224-8220 Fax: 410-841-2482 | |
Dr. Lisa A Dimarzio, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2003 Medical Parkway, Suite 100, Annapolis, MD 21401 Phone: 410-573-1110 Fax: 410-266-0714 | |
Dr. Richard A Bernstein, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 133 Defense Hwy, Suite 109, Annapolis, MD 21401 Phone: 401-224-5558 Fax: 410-224-7321 | |
Dr. Jonathan A Altschuler, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2002 Medical Pkwy, Ste 500, Annapolis, MD 21401 Phone: 410-573-6480 Fax: 410-573-9413 | |
Dr. Ira M Weinstein, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2000 Medical Pkwy, Suite 607, Annapolis, MD 21401 Phone: 410-266-1644 Fax: 410-266-1642 | |
Dr. James M Blake, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 820 Bestgate Road, Suite 2a, Annapolis, MD 21401 Phone: 410-224-2116 Fax: 410-224-2118 |